Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

September 22, 2021

Study Completion Date

June 27, 2022

Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
DRUG

K-321 Solution

K-321 solution drops

DRUG

Placebo Solution

Placebo solution drops for K-321

Trial Locations (29)

2000

Sydney Eye Hospital, Sydney

2600

Rigshospitalet - Glostrup, Glostrup Municipality

5000

Royal Adelaide Hospital, Adelaide

8035

Instituto de Microcirugia Ocular, Barcelona

8200

Aarhus Universitetshospital, Aarhus

10017

NY Langone Health, New York

14012

Hospital La Arruzafa, Córdoba

15213

UPMC Eye Center, Pittsburgh

19004

Vantage EyeCare, LLC, Bala-Cynwyd

32605

UF Health Eye Center, Gainesville

33012

Instituto Ophthalmologic Fernandez Vega, Oviedo

33907

Gorovoy MD Eye Specialists, Fort Myers

45242

Cincinnati Eye Institute, Cincinnati

46260

Price Vision Group, Indianapolis

48105

W Kellogg Eye Center, Ann Arbor

55431

Minnesota Eye Consultants, Bloomington

60169

Chicago Cornea Consultants Ltd, Hoffman Estates

60467

Arbor Centers For Eyecare, Orland Park

66421

Universität des Saarlandes, Homburg

87109

Eye Associates of New Mexico, Albuquerque

90095

Jules Stein Eye Institute, Los Angeles

91054

Universitätsklinikum Erlangen, Erlangen

94304

Byers Eye Institute at Stanford, Palo Alto

95817

UC Davis Eye Center, Sacramento

97210

Devers Eye Institute, Portland

97239

Casey Eye Institute - OHSU, Portland

98515

Sacramento Eye Consultants, Sacramento

02114

Massachusetts Eye and Ear Infirmary, Boston

08916

Hospital Universitario Germans Trias i Pujol, Badalona

Sponsors
All Listed Sponsors
lead

Kowa Research Institute, Inc.

INDUSTRY